Medifron DBT (065650) Stock Overview

Medifron DBT Co., Ltd., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and wheels; keyboards; headsets; webcams; and sound bars, as well as provides online contents. In addition, it manufactures and supplies frozen and room temperature convenience food products, such as frozen sticky rice and fish cakes, tteokbokki sauce, and raw materials for sauce under the Memories of Elementary School Tteokbokki, Newtro, and K-TOWN brands. The company was formerly known as Legend Technologies Inc. and changed its name to Medifron DBT Co., Ltd. in January 2006. Medifron DBT Co., Ltd. was founded in 1997 and is headquartered in Seoul, South Korea.